Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06701526 · ClinicalTrials.gov registry record · Phase 4
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications
A Phase 4 study of Migraine, sponsored by H. Lundbeck A/S.
- Active
- Registry status
- Phase 4
- Development phase
- 150
- Enrollment target
- 20
- Study locations
NCT06701526: Active Phase 4 study of Migraine, sponsored by H. Lundbeck A/S.
NCT06701526 is a Phase 4 study of Migraine that is active but no longer recruiting, run by H. Lundbeck A/S. The registered enrollment target is 150 participants, below the 357-participant average among 102 other Migraine trials with a reported enrollment target (58% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06701526, a Phase 4 study of Migraine, is active but no longer recruiting, sponsored by H. Lundbeck A/S.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 150 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main goal of this trial is to learn whether eptinezumab improves migraine symptoms and quality of life of participants with migraine who did not perceive a sufficient improvement during previous treatment with therapies targeting calcitonin gene-related peptide (CGRP).
Conditions Studied
Interventions
- DRUG Eptinezumab
Study Locations (20)
California
- Neuropain Medical Center - Fresno
- Sunwise Clinical Research, LLC. - Oakland
- The Neuron Clinic - San Marcos
Colorado
- St. Joseph's Hospital and Medical Center - Barrow Neurological Institute - Aurora
- Advanced Neurology of Colorado, LLC - Longmont
- Research of the Rockies - Parker
Massachusetts
- Neurology Center of New England P.C. - Foxborough
- MedVadis Research Corporation - Watertown
- Mass Institute of Clinical Research - Westborough
Connecticut
- Hasbani & Hasbani MDs - New Haven
- New England Institute for Neurology and Headache - Stamford
Florida
- Brainstorm Research - Miami
- Premiere Research Institute at Palm Beach Neurology - West Palm Beach
New York
- Albany Medical College - Albany
- Dent Neurosciences Research Center, Inc. - Amherst
Georgia
- PANDA Neurology and Atlanta Headache Specialists - Atlanta
Idaho
- St Luke's Meridian Medical Center - Meridian
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2024-12-18 |
| Est. Completion | 2026-06-05 |
| Phase | Phase 4 |
What the registry record for NCT06701526 still lists
NCT06701526 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 357-participant average among 102 other Migraine trials with a reported enrollment target (58% lower).
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 1 intervention - of which Eptinezumab is the first listed.
NCT06701526 names 20 study sites across 11 states, led by California, Colorado, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06701526 about?
NCT06701526 is a clinical study titled "A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications". The main goal of this trial is to learn whether eptinezumab improves migraine symptoms and quality of life of participants with migraine who did not perceive a sufficient improvement during previous treatment with therapies targeting calcitonin gene-related peptide (CGRP).
What is the current status of trial NCT06701526?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 150 participants. The study started on 2024-12-18. Estimated completion is 2026-06-05.
What conditions does trial NCT06701526 study?
This clinical trial studies the following conditions: Migraine.
What interventions are being tested in trial NCT06701526?
The interventions under investigation include: Eptinezumab (DRUG).
Who is sponsoring clinical trial NCT06701526?
This trial is sponsored by H. Lundbeck A/S, which has 72 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06701526 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06701526's enrollment target sits among peer trials
150 49th of 102 higher than 53 of 102 other Migraine trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Migraine trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Comparison of Nurtec ODT to Maxalt MLT-ODT in Adult ED Patients With Migraine Headache
RECRUITING · Phase 4
-
Effectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications
RECRUITING · Phase 4
-
Rimegepant as Preemptive Treatment for Predictable Trigger-Induced Migraine in Adult Patients in the US
RECRUITING · Phase 4
-
Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
RECRUITING · Phase 4
-
Nerivio Efficacy Under High-Frequency Use
ACTIVE NOT RECRUITING · Phase 4
-
Fremanezumab Treatment of Migraine in Women With Menstrual Migraine Ages 18-45
ACTIVE NOT RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI